Lipigon Pharmaceuticals AB (LPGO) - Net Assets
Based on the latest financial reports, Lipigon Pharmaceuticals AB (LPGO) has net assets worth Skr7.91 Million SEK (≈ $851.67K USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr11.49 Million ≈ $1.24 Million USD) and total liabilities (Skr3.57 Million ≈ $384.51K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Lipigon Pharmaceuticals AB to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr7.91 Million |
| % of Total Assets | 68.9% |
| Annual Growth Rate | -46.34% |
| 5-Year Change | -65.53% |
| 10-Year Change | N/A |
| Growth Volatility | 280.06 |
Lipigon Pharmaceuticals AB - Net Assets Trend (2017–2025)
This chart illustrates how Lipigon Pharmaceuticals AB's net assets have evolved over time, based on quarterly financial data. See LPGO cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Lipigon Pharmaceuticals AB (2017–2025)
The table below shows the annual net assets of Lipigon Pharmaceuticals AB from 2017 to 2025. For live valuation and market cap data, see Lipigon Pharmaceuticals AB market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr7.91 Million ≈ $851.67K |
+1.97% |
| 2024-12-31 | Skr7.76 Million ≈ $835.21K |
-72.71% |
| 2023-12-31 | Skr28.44 Million ≈ $3.06 Million |
+634.80% |
| 2022-12-31 | Skr3.87 Million ≈ $416.58K |
-83.14% |
| 2021-12-31 | Skr22.96 Million ≈ $2.47 Million |
+76.86% |
| 2020-12-31 | Skr12.98 Million ≈ $1.40 Million |
+498.57% |
| 2019-12-31 | Skr2.17 Million ≈ $233.42K |
+357.60% |
| 2018-12-31 | Skr-842.00K ≈ $-90.61K |
-100.07% |
| 2017-12-31 | Skr1.15 Billion ≈ $123.84 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Lipigon Pharmaceuticals AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 515300300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr787.00K | 9.95% |
| Other Components | Skr163.92 Million | 2071.49% |
| Total Equity | Skr7.91 Million | 100.00% |
Lipigon Pharmaceuticals AB Competitors by Market Cap
The table below lists competitors of Lipigon Pharmaceuticals AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TAURUS GOLD CORP.
F:W1N
|
$98.90K |
|
Altona Rare Earths PLC
LSE:REE
|
$99.37K |
|
INSURAGUEST TECHN. INC.
F:4JG
|
$99.69K |
|
Renalytix AI plc
LSE:RENX
|
$101.03K |
|
Livento Group Inc.
NASDAQ:NUGND
|
$97.64K |
|
AYURCANN HOLDINGS CORP.
F:3ZQ0
|
$97.35K |
|
Velocity Composites plc
LSE:VEL
|
$96.45K |
|
Autins Group plc
LSE:AUTG
|
$96.33K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lipigon Pharmaceuticals AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 7,760,000 to 7,913,000, a change of 153,000 (2.0%).
- Net loss of 32,438,000 reduced equity.
- New share issuances of 38,227,000 increased equity.
- Other comprehensive income increased equity by 999.
- Other factors decreased equity by 5,636,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-32.44 Million | -409.93% |
| Share Issuances | Skr38.23 Million | +483.09% |
| Other Comprehensive Income | Skr999.00 | +0.01% |
| Other Changes | Skr-5.64 Million | -71.24% |
| Total Change | Skr- | 1.97% |
Book Value vs Market Value Analysis
This analysis compares Lipigon Pharmaceuticals AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | Skr91.87 | Skr0.00 | x |
| 2018-12-31 | Skr-0.07 | Skr0.00 | x |
| 2019-12-31 | Skr0.17 | Skr0.00 | x |
| 2020-12-31 | Skr0.98 | Skr0.00 | x |
| 2021-12-31 | Skr1.87 | Skr0.00 | x |
| 2022-12-31 | Skr0.22 | Skr0.00 | x |
| 2023-12-31 | Skr0.44 | Skr0.00 | x |
| 2024-12-31 | Skr0.06 | Skr0.00 | x |
| 2025-12-31 | Skr0.02 | Skr0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lipigon Pharmaceuticals AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -409.93%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.45x
- Recent ROE (-409.93%) is below the historical average (-275.92%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -263.35% | 0.00% | 0.00x | 1.54x | Skr-3.15 Billion |
| 2018 | 0.00% | -125600.00% | 0.01x | 0.00x | Skr-3.68 Million |
| 2019 | -227.48% | -283.08% | 0.54x | 1.48x | Skr-5.15 Million |
| 2020 | -62.14% | -188.59% | 0.28x | 1.17x | Skr-9.37 Million |
| 2021 | -179.07% | -1293.02% | 0.11x | 1.28x | Skr-43.41 Million |
| 2022 | -973.08% | -9658.46% | 0.04x | 2.79x | Skr-38.06 Million |
| 2023 | -42.64% | -73.92% | 0.49x | 1.18x | Skr-14.97 Million |
| 2024 | -325.57% | -245.59% | 0.69x | 1.91x | Skr-26.04 Million |
| 2025 | -409.93% | 0.00% | 0.00x | 1.45x | Skr-33.23 Million |
Industry Comparison
This section compares Lipigon Pharmaceuticals AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $210,830,100
- Average return on equity (ROE) among peers: -92.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lipigon Pharmaceuticals AB (LPGO) | Skr7.91 Million | -263.35% | 0.45x | $97.81K |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $5.43 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $41.37 Million |
| AcouSort AB (ACOU) | $9.59 Million | -85.70% | 0.37x | $9.66 Million |
| Active Biotech AB (ACTI) | $181.76 Million | -121.63% | 1.77x | $103.60 Million |
| Alzinova AB (ALZ) | $113.86 Million | -14.47% | 0.08x | $8.00 Million |
| AlzeCure Pharma (ALZCUR) | $26.18 Million | -134.56% | 0.32x | $45.63 Million |
| Annexin Pharmaceuticals AB (ANNX) | $11.49 Million | -247.14% | 0.40x | $9.12 Million |
| Alligator Bioscience AB (ATORX) | $89.05 Million | -217.18% | 0.90x | $11.46 Million |
| BioInvent International AB (BINV) | $1.37 Billion | -20.41% | 0.06x | $166.42 Million |
| BioArctic AB (publ) (BIOA-B) | $108.28 Million | 3.43% | 0.21x | $2.36 Billion |
About Lipigon Pharmaceuticals AB
Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which… Read more